deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT02351037

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia

Sponsor: Pharmacyclics LLC.

Conditions Acute Myeloid Leukemia (AML)
Interventions Ibrutinib Ibrutinib + LD-AraC Ibrutinib+Azacitidine
Updated 12 times since 2017 Last updated: Jul 18, 2018 Started: Feb 28, 2015 Primary completion: Apr 30, 2017 Completion: Apr 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study data do not support development in AML.

Other terminated trials from Pharmacyclics LLC.

More terminations from Pharmacyclics LLC.

Other Acute Myeloid Leukemia (AML) trials with similar outcome

Browse all Acute Myeloid Leukemia (AML) trials

This PHASE2 trial investigates Acute Myeloid Leukemia (AML) and is currently terminated or withdrawn. Pharmacyclics LLC. leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshotActive Not Recruiting~Jun 2017 – ~May 2018 · 11 months · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotTerminated~Sep 2018 – ~Jan 2021 · 28 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 12 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Terminated PHASE2

  2. Sep 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Jun 2018 — Sep 2018 [monthly]

    Terminated PHASE2

  4. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  5. Jun 2017 — May 2018 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  6. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pharmacyclics LLC.
Data source: Pharmacyclics LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations